266 related articles for article (PubMed ID: 19174487)
21. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Cheng CL; Johnson SP; Keir ST; Quinn JA; Ali-Osman F; Szabo C; Li H; Salzman AL; Dolan ME; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2005 Sep; 4(9):1364-8. PubMed ID: 16170028
[TBL] [Abstract][Full Text] [Related]
22. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Palma JP; Rodriguez LE; Bontcheva-Diaz VD; Bouska JJ; Bukofzer G; Colon-Lopez M; Guan R; Jarvis K; Johnson EF; Klinghofer V; Liu X; Olson A; Saltarelli MJ; Shi Y; Stavropoulos JA; Zhu GD; Penning TD; Luo Y; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
Anticancer Res; 2008; 28(5A):2625-35. PubMed ID: 19035287
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE; Adamson PC; Nguyen VT; Fox E
Pediatr Blood Cancer; 2014 Jan; 61(1):145-50. PubMed ID: 24038812
[TBL] [Abstract][Full Text] [Related]
24. Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Murai J; Zhang Y; Morris J; Ji J; Takeda S; Doroshow JH; Pommier Y
J Pharmacol Exp Ther; 2014 Jun; 349(3):408-16. PubMed ID: 24650937
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
27. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.
Tentori L; Portarena I; Vernole P; De Fabritiis P; Madaio R; Balduzzi A; Roy R; Bonmassar E; Graziani G
Cancer Chemother Pharmacol; 2001 Apr; 47(4):361-9. PubMed ID: 11345654
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.
Xie Z; Zhou Y; Zhao W; Jiao H; Chen Y; Yang Y; Li Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4557-61. PubMed ID: 26342868
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
[TBL] [Abstract][Full Text] [Related]
30. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Miknyoczki SJ; Jones-Bolin S; Pritchard S; Hunter K; Zhao H; Wan W; Ator M; Bihovsky R; Hudkins R; Chatterjee S; Klein-Szanto A; Dionne C; Ruggeri B
Mol Cancer Ther; 2003 Apr; 2(4):371-82. PubMed ID: 12700281
[TBL] [Abstract][Full Text] [Related]
31. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
32. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
Muñoz-Gámez JA; López Viota J; Barrientos A; Carazo Á; Sanjuán-Nuñez L; Quiles-Perez R; Muñoz-de-Rueda P; Delgado Á; Ruiz-Extremera Á; Salmerón J
Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
[TBL] [Abstract][Full Text] [Related]
33. Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
He JX; Wang M; Huan XJ; Chen CH; Song SS; Wang YQ; Liao XM; Tan C; He Q; Tong LJ; Wang YT; Li XH; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Gao ZW; Chen XY; Xiong B; Lu XL; Ding J; Yang CH; Miao ZH
Oncotarget; 2017 Jan; 8(3):4156-4168. PubMed ID: 27926532
[TBL] [Abstract][Full Text] [Related]
34. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
Jun HT; Sun J; Rex K; Radinsky R; Kendall R; Coxon A; Burgess TL
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6735-42. PubMed ID: 18006775
[TBL] [Abstract][Full Text] [Related]
35. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer R; Lorigan P; Steven N; Scott L; Middleton MR; Wilson RH; Mulligan E; Curtin N; Wang D; Dewji R; Abbattista A; Gallo J; Calvert H
Cancer Chemother Pharmacol; 2013 May; 71(5):1191-9. PubMed ID: 23423489
[TBL] [Abstract][Full Text] [Related]
37. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
39. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
Croucher JL; Iyer R; Li N; Molteni V; Loren J; Gordon WP; Tuntland T; Liu B; Brodeur GM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):131-41. PubMed ID: 25394774
[TBL] [Abstract][Full Text] [Related]
40. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
